Term
| Emil Kraepelin used this term for the "condition" of schizophrenia in 1800s |
|
Definition
|
|
Term
| Eugen Bleuler coined the term in 1911 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| not associated with multiple personalities; symptoms are positive and negative |
|
Definition
|
|
Term
| risk of 1st degree relative w/ schizophrenia |
|
Definition
|
|
Term
| risk for children with 2 parents with schizophrenia |
|
Definition
|
|
Term
| avolition, affective flattening, alogia |
|
Definition
|
|
Term
| delusions, hallucinations, disorganized speech, tactile symptoms (touch) |
|
Definition
|
|
Term
| risk of 1st degree relative w/ schizophrenia |
|
Definition
|
|
Term
| risk for children with 2 parents with schizophrenia |
|
Definition
|
|
Term
| avolition, affective flattening, alogia |
|
Definition
|
|
Term
| delusions, hallucinations, disorganized speech, tactile symptoms (touch) |
|
Definition
|
|
Term
| prominent delusions or hallucinations |
|
Definition
|
|
Term
| disorganized speech, behavior, and/or inappropriate affect |
|
Definition
|
|
Term
| motoric changes, extreme negativism and/or echolalia/echopraxia |
|
Definition
|
|
Term
| criteria not met by other subtypes |
|
Definition
|
|
Term
| prominent positive symptoms absent, continuing negative symptoms |
|
Definition
|
|
Term
| delusions, hallucinations, disorganized speech, psychomotor agitation |
|
Definition
|
|
Term
| affective flattening, alogia (don't talk much), avolition (don't move much), poverty of speech, anhedonia (don't feel pleasure) |
|
Definition
|
|
Term
| attention, memory, executive functioning |
|
Definition
|
|
Term
| hyperactivity in limbic system leading to positive symptoms; hypofunctioning in prefrontal cortex leading to negative symptoms |
|
Definition
|
|
Term
| Glutamate dyfunction correlates with increased psychiatric symptoms |
|
Definition
|
|
Term
| leads to cognitive symptoms |
|
Definition
| acetylcholine hypoactivity (nicotinic receptors) |
|
|
Term
| reduce threat to self and others; reduce acute symptoms; improve role functioning; minimize adverse effects |
|
Definition
|
|
Term
| minimize/prevent treatment relapse; treatment adherence; optimize dose for maximizing response and minimizing adverse effects |
|
Definition
|
|
Term
| improve function and quality of life; optimize dose and minimize adverse reactions; continue treatment adherence |
|
Definition
|
|
Term
| antagonism of dopamine D-2 receptors |
|
Definition
| first generation antipsychotics |
|
|
Term
| First generation antipsychotics |
|
Definition
| primarily effective for positive symptoms; notable for association with motor symptoms and secondary negative symptoms |
|
|
Term
| Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Molindine, Perpheazine, Pimozide, Thioridazine, Thiothexine, Trifluperazine |
|
Definition
| First Generation Antipsychotics |
|
|
Term
| involuntary tonic contraction of skeletal muscles (adverse effect) |
|
Definition
|
|
Term
| rigidity, tremors, bradykinesia (adverse effect) |
|
Definition
|
|
Term
| subjective inner restlessness: fidgeting, pacing (adverse effect) |
|
Definition
|
|
Term
| stereotypical involuntary movements (e.g., sucking and lip smacking) (adverse effect) |
|
Definition
|
|
Term
| treatment of acute dystonia |
|
Definition
|
|
Term
| treatment of pseudo-parkinsoniam |
|
Definition
|
|
Term
|
Definition
| beta-blockers, benzodiazepines |
|
|
Term
| treatment of tardive dyskinesia |
|
Definition
| focus on preventions; may use clozapine |
|
|
Term
|
Definition
|
|
Term
| onset of pseudo-parkinsonism |
|
Definition
|
|
Term
|
Definition
|
|
Term
| onset of tardive dyskinesia |
|
Definition
|
|
Term
| high risk for acute dystonia |
|
Definition
|
|
Term
| high risk of pseudo-parkinsonism |
|
Definition
|
|
Term
|
Definition
|
|
Term
| high risk of tardive dyskinesia |
|
Definition
| older females; history of mood disorders |
|
|
Term
| has high sedative effects, moderate hypotensive effects |
|
Definition
|
|
Term
| life threatening disease: muscular rigidity, hyperthermia, change in mental status, autonomic dysfunction |
|
Definition
| Neuroleptic Malignant Syndrome (NMS) |
|
|
Term
| Treat with hydration and cooling blankets; bromocriptine and/or dantrolene may be useful |
|
Definition
|
|
Term
|
Definition
| from dopamine blockade in hypothalamus; may result in gynecomastia, amenorrhea, and sexual dysfunction |
|
|
Term
| secondary negative symptoms |
|
Definition
| reduced initiative, interest in environment, emotion or affect |
|
|
Term
|
Definition
| allergic-maculopapular rash, localize or general urticaria; photosensitivity reaction |
|
|
Term
| other antipsychotic adverse events |
|
Definition
| cardiac, lowering seizure threshold, hepatic function |
|
|
Term
| antagonism of D2, D1 and Serotonin receptors; effective for positive and negative symptoms |
|
Definition
|
|
Term
| Clozapine, Risperidone, Olanzapine, Quetiapine, Ziprazidone, Aripiprazole, Paliperidone, Ilopendone, Asenapine, Lurasidone |
|
Definition
| Second Generations Antipsychotics |
|
|
